While studies with SGLT2 inhibitors have been conducted almost entirely in the diabetes, this drug class lowers tubular glucose reabsorption sufficiently to induce glycosuria in both animal models and human subjects without hyperglycaemia [12–16]. This evidence concerns the gene SLC5A2 and Hyperglycemia.